Cupid Ltd Board Approves 49% Stake in South African Joint Venture

MUMBAI, August 28, 2026 — Cupid Limited announced on Friday that its Board of Directors has granted in-principle approval to establish a manufacturing venture in South Africa with a local partner. Under the proposed agreement, the Mumbai-listed consumer wellness firm will hold up to a 49 percent equity stake, with the remaining 51 percent held by the South African partner and local qualifying shareholders to meet regional transformation and tender requirements.

The announcement marks a strategic expansion for Cupid Limited, positioning the firm to capitalize on local public healthcare procurement and regional demand across the African continent.

Strategic Localisation Drive in South Africa

The planned facility in South Africa will cover the manufacturing, processing, testing, packaging, marketing, and distribution of male condoms and related products. South African public procurement rules place strong emphasis on domestic manufacturing, local value addition, and supply chain resilience.

By structuring the equity split at 49-51 percent, the new venture complies with local ownership, transformation, and tender rules. Cupid Limited has participated in South Africa's public healthcare sector for years and currently bids via local partners in the five-year RT75-2025 tender for male and female condoms. Establishing a physical manufacturing presence strengthens the company's long-term commercial positioning in the region.

Asset-Light Capital Structure and Technology Transfer

Under the terms of the in-principle approval, the project utilizes an asset-light model for Cupid Limited. The local South African partner will arrange the capital expenditure for facility setup and operational funding.

Cupid Limited's contribution will focus on operational and technical support:

• Technical expertise and industry know-how

• Technology transfer support and quality-control systems

• Workforce training and operational guidance

Platform for Regional and Global Expansion

The South African manufacturing plant is expected to act as a regional operational hub. In addition to meeting domestic demand and institutional procurement needs in South Africa, the hub is designed to support market expansion into broader African territories and potential international export destinations in the Western Hemisphere, subject to regulatory clearances.

Alongside this international expansion, Cupid Limited is boosting domestic capacity via its upcoming facility in Palava, India, to serve both global B2B healthcare demand and domestic fast-moving consumer goods (FMCG) lines.

Official Statements

The company formally disclosed the board approval to Indian financial markets in regulatory filings on Friday.

According to official filings with BSE Limited and the National Stock Exchange of India, the board’s in-principle approval remains subject to the execution of definitive agreements, entity incorporation, and statutory filings.

Executive Commentary

Aditya Kumar Halwasiya, Chairman & Managing Director of Cupid Limited, highlighted the strategic intent behind the joint venture in an official company release.

"South Africa is an important and strategically attractive market for Cupid Limited," Halwasiya stated. "The proposed venture combines our manufacturing expertise and established quality systems with strong local capabilities, while aligning with the country's increasing focus on domestic manufacturing and local value addition. We believe the initiative has the potential to create value for the South African healthcare ecosystem, local communities, business partners and our shareholders."

Why It Matters

The establishment of a manufacturing base in South Africa allows Cupid Limited to secure a strong local footprint without deploying heavy capital expenditure. For institutional healthcare buyers, the move promises a localized, resilient supply chain for essential wellness products. For investors, it offers exposure to expanded market share across Africa while preserving capital efficiency through an asset-light corporate structure.

Key Facts at a Glance

• Equity Split: Cupid Limited will hold up to 49 percent equity, while the local partner holds at least 51 percent.

• Capital Arrangement: Plant setup costs and working capital will be arranged by the South African partner.

• Core Contribution: Cupid Limited supplies technology transfer, quality control systems, and manufacturing know-how.

• Target Products: Manufacture, testing, packaging, and distribution of male condoms and related products.

• Regulatory Compliance: Designed to satisfy South African domestic localisation, transformation, and public tender guidelines.

Frequently Asked Questions (FAQ)

What is Cupid Limited's shareholding in the new South African venture?

Cupid Limited is expected to hold up to a 49 percent equity stake, with at least 51 percent held by the South African partner to fulfill local transformation and regulatory criteria.

Who is funding the construction and operations of the new facility?

The required capital expenditure, working capital, and operating funds will be arranged by the South African partner, making the expansion asset-light for Cupid Limited.

What will Cupid Limited provide to the joint venture?

Cupid Limited will provide technical expertise, manufacturing know-how, technology transfer support, quality control systems, and staff training.

Is this joint venture final?

The Board of Directors has granted in-principle approval. The venture remains subject to the finalization and execution of definitive agreements and entity incorporation.

Source: BSE Limited regulatory filings, National Stock Exchange of India regulatory filings, and official Cupid Limited press releases published August 28, 2026.